AcoArt VI / Vertebral Artery Ostium Stenosis in China
Prospective, Multi-center and Randomized Controlled Clinical Study to Verify Effectiveness and Safety of Drug-eluting Balloon in PTA Procedure of Vertebral Artery Ostium Stenosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Vertebral Artery Origin Stenting is an established alternative to open surgical bypass for the treatment of Vertebral Artery Ostium Stenosis .
DEBs are designed to promote arterial patency by reducing neointimal proliferation.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Liqun Jiao
- Phone Number: 13911224991
- Email: DOCTOR_K@163.com
Study Locations
-
-
-
Beijing, China
- Xuanwu Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- aged between 18 and 80 years old
- symptomatic VAO stenosis refractory to AMM (aggressive medical management)
- etiology of VAOS was atherosclerosis
- the diameter of the normal segment of the artery beyond the stenosis between 3mm and 5mm
- Target lesion has stenosis ≥ 70% evidenced by angiography
- Score on the modified Rankin scale ≤ 3
- NIHSS≤ 6
- Patients have signed informed consent
Exclusion Criteria:
- In-stent restenosis in vertebral artery
- Severe calcified lesion or residual stenosis ≥30% after predilatation or flow-limiting dissection
- Tortuous or variable vessels
- distal serial stenosis or distal vascular dysplasia of the stenosis segment
- Non-atherosclerotic arterial stenosis
- Non-vertebral artery stenosis caused TIA or stroke
- intracranial stent implantation within 12 months
- Intracranial hemorrhage occurred within 3 months
- Obvious thrombosis in brain vessel, or have received thrombolytic therapy 24 hours before procedure
- Active bleeding or coagulation disorders
- Serious liver/kidney damage, not suitable for routine surgical treatment
- Myocardial infarction or extensive cerebral infarction occurred within 2 weeks
- Uncontrolled high blood pressure
- Complicated intracranial tumor, cerebral arteriovenous malformation, or intracranial aneurysm
- Potential sources of cardiogenic thrombosis, such as mitral stenosis, atrial septal defect, aorta or mitral valve replacement, left atrial myxoma, etc
- Life expectancy shorter than 1 years
- Patients whit cognitive impairment or mental disorders
- Known hypersensitivity to aspirin, heparin, clopidogrel,paclitaxel, contrast medium, etc
- Pregnant and lactating women
- Patients who have participated in other clinical trials during the same period that lead to researchers who believe that patients may not be able to follow the trial program
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: DCB group
use DEB catheter(trade name:Orchid/Dhalia) to treat the stenosis or occlusion in Vertebral Artery Ostium Stenosis of experimental arm
|
After predilation, using drug-coated balloon catheter to cover the whole treated segment
|
|
Active Comparator: BMS group
use Intracranial artery stent system(trade name:Apollo) to treat stenosis or occlusion in Vertebral Artery Ostium Stenosis of control group
|
stent assisted angioplasty
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of target lesion restenosis
Time Frame: 12Months
|
Target Lesion Restenosis(diameter stenosis ≥50%) under DSA at 12 Months or diamater stenosis ≥50% under DSA before Target Lesion Revascularization within 12 Months
|
12Months
|
|
Rate of device success
Time Frame: during the operation
|
DEB group: DEB catheter can reach the target lesions, expand as expected (not broken),and withdraw successfully.
BES group: the stenosis rate of proximal outflow less than 50% with intervention and no ischemia or hemorrhage occurred.
|
during the operation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of device success
Time Frame: during the operation
|
DEB group: DEB catheter can reach the target lesions, expand as expected (not broken),and withdraw successfully.
BES group: the stenosis rate of proximal outflow less than 50% with intervention and no ischemia or hemorrhage occurred.
|
during the operation
|
|
Incidence of hemorrhagic stroke and posterior circulation ischemic stroke
Time Frame: 12 Months
|
incidence of hemorrhagic stroke and posterior circulation ischemic stroke within 12 months
|
12 Months
|
|
Incidence of transient ischemic attack of posterior circulation
Time Frame: 12 Months
|
incidence of transient ischemic attack of posterior circulation within 12 months
|
12 Months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Liqun Jiao, PhD, Xuanwu Hospital, Beijing
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Acotec-06
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.